Liu Xiao-Yue, Zhang Xi, Ruan Guo-Tian, Zhang Kang-Ping, Tang Meng, Zhang Qi, Song Meng-Meng, Zhang Xiao-Wei, Ge Yi-Zhong, Yang Ming, Xu Hong-Xia, Song Chun-Hua, Shi Han-Ping
Department of Gastrointestinal Surgery/Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, People's Republic of China.
Department of Oncology, Capital Medical University, Beijing, 100038, People's Republic of China.
Cancer Manag Res. 2021 Aug 29;13:6775-6783. doi: 10.2147/CMAR.S318728. eCollection 2021.
Serum albumin can indicate the onset of cancer cachexia, provide information about a patient's nutritional status, and serve as a biomarker for the prognosis of patients with cancer cachexia. However, the relationship between serum albumin levels and mortality in patients with cancer cachexia remains unclear. We aimed to examine the association of albumin and total protein with 1-year mortality in patients with cancer cachexia.
We conducted a nested case-control study using data from a multicenter cancer clinical survey from 2013 to 2018. In total, 266 patients with cancer cachexia who survived for <1 year and 266 patients who survived for ≥1 year were included in this study. The participants were matched by age, sex, tumor type, tumor stage, and hospital site. The crude and adjusted risks of 1-year survival were estimated using odds ratios (ORs) and 95% confidence intervals (95% CIs) using logistic regression, with or without adjustment for covariates.
Logistic regression analysis revealed a significantly negative linear association between albumin level and 1-year mortality in patients with cancer cachexia (p < 0.001). An L-shaped relationship existed between total protein and 1-year mortality, with a turning point at 70.4 g/L. When albumin was divided into quartiles, Q3 (OR: 0.40; 95% CI: 0.24, 0.68; p < 0.001) and Q4 (OR: 0.33; 95% CI: 0.19, 0.55; p < 0.001) were associated with higher 1-year survival than Q1 among patients with cancer cachexia. When total protein was divided into quartiles, Q2 (OR: 0.38; 95% CI: 0.23, 0.64; p < 0.001), Q3 (OR: 0.57; 95% CI: 0.33, 0.96; p = 0.035), and Q4 (OR: 0.43; 95% CI: 0.25, 0.72; p = 0.002) were associated with higher 1-year survival than Q1 among patients with cancer cachexia.
Serum albumin and total protein may predict 1-year survival. Future clinical studies should lead to a more comprehensive understanding of the effects of serum protein levels in patients with cancer cachexia.
血清白蛋白可提示癌症恶病质的发生,提供患者营养状况信息,并作为癌症恶病质患者预后的生物标志物。然而,癌症恶病质患者血清白蛋白水平与死亡率之间的关系仍不明确。我们旨在研究白蛋白和总蛋白与癌症恶病质患者1年死亡率之间的关联。
我们利用2013年至2018年多中心癌症临床调查的数据进行了一项巢式病例对照研究。本研究共纳入266例存活时间<1年的癌症恶病质患者和266例存活时间≥1年的患者。参与者按年龄、性别、肿瘤类型、肿瘤分期和医院地点进行匹配。使用比值比(OR)和95%置信区间(95%CI),通过逻辑回归估计1年生存的粗风险和调整风险,对协变量进行或不进行调整。
逻辑回归分析显示,癌症恶病质患者白蛋白水平与1年死亡率之间存在显著的负线性关联(p<0.001)。总蛋白与1年死亡率之间存在L形关系,转折点为70.4g/L。将白蛋白分为四分位数时,在癌症恶病质患者中,Q3(OR:0.40;95%CI:0.24,0.68;p<0.001)和Q4(OR:0.33;95%CI:0.19,0.55;p<0.001)与Q1相比,1年生存率更高。将总蛋白分为四分位数时,在癌症恶病质患者中,Q2(OR:0.38;95%CI:0.23,0.64;p<0.001)、Q3(OR:0.57;95%CI:0.33,0.96;p=0.035)和Q4(OR:0.43;95%CI:0.25,0.72;p=0.002)与Q1相比,1年生存率更高。
血清白蛋白和总蛋白可能预测1年生存率。未来的临床研究应能更全面地了解血清蛋白水平对癌症恶病质患者的影响。